Docoh
Loading...

NANX NANOPHASE TECHNOLOGIES

Nanophase Technologies Corp. engages in the development and provision of engineered nanomaterial solutions. Its products include metal oxides with aluminum, antimony tin, bismuth, cerium, iron, and zinc. The firm's product is used in variety of markets including surface finishing, exterior coatings, personal care, plastics, scratch resistant coatings, and textiles. The company was founded by Richard W. Siegel on November 25, 1989 and is headquartered in Romeoville, IL.

Company profile

Ticker
NANX
Exchange
CEO
Jess A. Jankowski
Employees
Incorporated
Location
Fiscal year end
Former names
NANOPHASE TECHNOLOGIES CORPORATION
SEC CIK
IRS number
363687863

NANX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 May 21
24 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1.82M 1.82M 1.82M 1.82M 1.82M 1.82M
Cash burn (monthly) (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn) 45.67K 84.83K
Cash used (since last report) n/a n/a n/a n/a 127.25K 236.4K
Cash remaining n/a n/a n/a n/a 1.69M 1.58M
Runway (months of cash) n/a n/a n/a n/a 37.0 18.7

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
7 May 21 Whitmore Bradford T Common Stock Conversion Aquire C No No 0.2 10,095,555 2.02M 29,625,290
7 May 21 Whitmore Bradford T 2% Second Secured Convertible Note Common Stock Conversion Dispose C No No 0.2 2,019,111 403.82K 0
23 Dec 20 Whitmore R Janet Common Stock Buy Aquire P No No 0.75 50,000 37.5K 1,467,055
8 Dec 20 Whitmore R Janet Common Stock Buy Aquire P No No 0.76 19,100 14.52K 1,417,055
30 Nov 20 Whitmore R Janet Common Stock Buy Aquire P No No 0.68 700 476 1,397,955
28 Oct 20 Laura M Beres Common Stock Common Stock Grant Aquire A No No 0.62 10,000 6.2K 10,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

1.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 0 1 EXIT
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 601.41K 601.41K
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Whitmore Bradford T 601.41K $0 0.0%
Largest transactions
Shares Bought/sold Change
Whitmore Bradford T 601.41K 0 0.0%

Financial report summary

?
Management Discussion
  • Total revenue increased to $7,072,000 for the three months ended March 31, 2021, compared to $4,039,000 for the same period in 2020.
  • A substantial majority of our revenue for both periods was from our five largest customers, in particular, sales to our largest customer in skin care and sunscreen applications, medical diagnostics, and now finished skin health products marketed through our Solésence subsidiary. Product revenue, the primary component of our total revenue, increased to $7,050,000 three months ended March 31, 2021, compared to $3,961,000 during the same period of 2020. This increase was due to continued growth in the adoption of our Solésence® products and our medical diagnostics materials, offset by a decrease in revenue from our largest customer in our personal care ingredients business. 
  • Other revenue decreased to $22,000 for the three months ended March 31, 2021, compared to $78,000 for the three months ended March 31, 2020. Other revenue is typically comprised primarily of developmental or licensing fees. For the three months ended March 31, 2020, other revenue included $65,000 to development fees recognized for the Company’s work on behalf of a customer relating to new personal care ingredients.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Good
New words: appetite, biggest, burst, Chain, chose, confluence, constrained, core, cosmetic, curb, cyclicality, deep, deliver, enable, enabled, enhance, enhanced, enhancing, February, fight, floor, grown, handling, ingredient, innovation, instance, IRC, issue, knowledge, legacy, Leveraging, markedly, maximize, met, multiple, packaging, PCR, Pharmaceutical, platform, play, Polymerase, postponed, predict, professional, proven, rapidly, recognition, reoriented, request, requesting, science, serve, shown, slightly, storage, unexpected, unprecedented, viral, wellbeing
Removed: Accounting, achieve, achievement, Aid, approve, arise, assuming, authorization, aware, began, belief, Board, calculate, carry, case, cease, chemical, classified, clear, coated, Codification, commencement, commitment, consulting, consumer, contingent, continuation, contractual, corporate, declared, deferred, designated, determine, Division, duration, earned, enter, essential, estimate, expiration, extended, fee, fluid, fulfill, global, Governor, healthcare, inaccurate, indefinitely, infrastructure, initial, input, investor, JDA, Joint, jointly, law, low, manage, model, nanocrystalline, national, negative, ongoing, Organization, OTC, outbreak, outlook, pandemic, presentation, proportionally, qualify, quantifiable, realized, recent, recognizing, reduction, refunded, Relief, remuneration, return, SCOA, skincare, state, subsequently, Sumitomo, table, taxable, Title, transaction, unknowable, visibility, vital, world, worldwide